Twenty-seven percent of 50 heavily pretreated patients with stage IV breast cancer saw clinical benefit from the drug, with at least “stable disease” at 24 or more weeks after the start of treatment.
10-Jan-2017 1:05 PM EST Add to Favorites
A University of Colorado Cancer Center paper published today in the journal Nature Nanotechnology details how the immune system recognizes nanoparticles, potentially paving the way to counteract or avoid this detection.
16-Dec-2016 1:40 PM EST Add to Favorites
Prediction model created by "research parasites" published today in Lancet Oncology offers a more accurate prognosis for a patient's metastatic castration-resistant prostate cancer
15-Nov-2016 6:30 PM EST Add to Favorites
University of Colorado Cancer Center study published in the journal Gynecologic Oncology shows that only 44 percent of patients in a large, national sample received all three components of standard-of-care treatment, most often lacking brachytherapy.
31-Oct-2016 3:05 PM EDT Add to Favorites
University of Colorado Cancer Center study shows that comparing cancer cell sequencing results to published reference genomes may be less accurate than comparing to healthy cell from same organism.
27-Oct-2016 1:05 PM EDT Add to Favorites
"After chemo, PI3K helps the cell shut down and weather the storm. Then when the chemo is gone, PI3K helps cancer stem cells start back up again," says University of Colorado Cancer Center investigator, Antonio Jimeno, MD, PhD.
14-Sep-2016 2:00 PM EDT Add to Favorites
New understanding stops bladder cancer's ability to stop the tumor-suppressing gene RhoDGI2, thus allowing its initial action to proceed.
9-Sep-2016 11:05 AM EDT Add to Favorites
University of Colorado Cancer Center investigators unpack the mechanism of investigational drug, AMPI-109, showing its inactivation of PRL-3 flips an important switch on triple-negative breast cancer.
29-Aug-2016 2:05 PM EDT Add to Favorites
27-Jul-2015 11:05 AM EDT
An education session presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 details the challenges of collaboration between oncologists and pathologists in the context of molecular testing patient tumor samples.
30-May-2014 4:00 PM EDT